107 related articles for article (PubMed ID: 2066805)
41. Direct 99mTc labeling of monoclonal antibodies: radiolabeling and in vitro stability.
Garron JY; Moinereau M; Pasqualini R; Saccavini JC
Int J Rad Appl Instrum B; 1991; 18(7):695-703. PubMed ID: 1787078
[TBL] [Abstract][Full Text] [Related]
42. Evaluation of the 323/A3 monoclonal antibody and the use of technetium-99m-labeled 323/A3 Fab' for the detection of pan adenocarcinoma.
Pak KY; Nedelman MA; Fogler WE; Tam SH; Wilson E; Van Haarlem LJ; Colognola R; Warnaar SO; Daddona PE
Int J Rad Appl Instrum B; 1991; 18(5):483-97. PubMed ID: 1917518
[TBL] [Abstract][Full Text] [Related]
43. Enhanced kidney clearance with an ester-linked 99mTc-radiolabeled antibody Fab'-chelator conjugate.
Weber RW; Boutin RH; Nedelman MA; Lister-James J; Dean RT
Bioconjug Chem; 1990; 1(6):431-7. PubMed ID: 2099189
[TBL] [Abstract][Full Text] [Related]
44. Technetium-99 m labelling of DD-3B6/22 antifibrin monoclonal antibody fragment Fab' for thrombus imaging.
Lee FT; Boniface GR; Lambrecht RM; Rylatt DB; Bundesen PG
Immunol Cell Biol; 1993 Apr; 71 ( Pt 2)():117-24. PubMed ID: 8486395
[TBL] [Abstract][Full Text] [Related]
45. Site-specific 99mTc-labeling of antibody using dihydrazinophthalazine (DHZ) conjugation to Fc region of heavy chain.
Jeong JM; Lee J; Paik CH; Kim DK; Lee DS; Chung JK; Lee MC
Arch Pharm Res; 2004 Sep; 27(9):961-7. PubMed ID: 15473668
[TBL] [Abstract][Full Text] [Related]
46. Tissue distribution properties of technetium-99m-diamide-dimercaptide complexes and potential use as renal radiopharmaceuticals.
Kasina S; Fritzberg AR; Johnson DL; Eshima D
J Med Chem; 1986 Oct; 29(10):1933-40. PubMed ID: 3761312
[TBL] [Abstract][Full Text] [Related]
47. A novel method for the non-chromatographic purification of technetium-99m-labeled monoclonal antibodies: a study with B72.3 monoclonal antibody.
Rosenzweig HS; Ranadive GN; Seskey T; Epperly MW; Bloomer WD
Nucl Med Biol; 1994 Feb; 21(2):171-8. PubMed ID: 9234280
[TBL] [Abstract][Full Text] [Related]
48. Technetium-99m-human serum albumin: evaluation of a commercially produced kit.
Callahan RJ; McKusick KA; Lamson M; Castronovo FP; Potsaid MS
J Nucl Med; 1976 Jan; 17(1):47-9. PubMed ID: 1244447
[TBL] [Abstract][Full Text] [Related]
49. Technetium-99m labeling of antibodies to cardiac myosin Fab and to human fibrinogen.
Khaw BA; Strauss HW; Carvalho A; Locke E; Gold HK; Haber E
J Nucl Med; 1982 Nov; 23(11):1011-9. PubMed ID: 7131084
[TBL] [Abstract][Full Text] [Related]
50. The development of technetium-99m-labelled interleukin-2: a new radiopharmaceutical for the in vivo detection of mononuclear cell infiltrates in immune-mediated diseases.
Chianelli M; Signore A; Fritzberg AR; Mather SJ
Nucl Med Biol; 1997 Aug; 24(6):579-86. PubMed ID: 9316088
[TBL] [Abstract][Full Text] [Related]
51. Technetium-99m radiolabeling using a phage-derived single-chain Fv with a C-terminal cysteine.
Verhaar MJ; Keep PA; Hawkins RE; Robson L; Casey JL; Pedley B; Boden JA; Begent RH; Chester KA
J Nucl Med; 1996 May; 37(5):868-72. PubMed ID: 8965166
[TBL] [Abstract][Full Text] [Related]
52. Direct labeling of proteins with 99mTc.
Rhodes BA
Int J Rad Appl Instrum B; 1991; 18(7):667-76. PubMed ID: 1787075
[TBL] [Abstract][Full Text] [Related]
53. Preparation and use of NHS-MAG3 for technetium-99m labeling of DNA.
Winnard P; Chang F; Rusckowski M; Mardirossian G; Hnatowich DJ
Nucl Med Biol; 1997 Jul; 24(5):425-32. PubMed ID: 9290078
[TBL] [Abstract][Full Text] [Related]
54. Formulation development of an antifibrin monoclonal antibody radiopharmaceutical.
Kamat MS; Tolman GL; Brown JM
Pharm Biotechnol; 1996; 9():343-64. PubMed ID: 8914198
[TBL] [Abstract][Full Text] [Related]
55. Structure-activity relationships of some technetium-99m labeled [(thioethyl)amino] carboxylates.
Chiotellis E; Stassinopoulou CI; Varvarigou A; Vavouraki H
J Med Chem; 1982 Nov; 25(11):1370-4. PubMed ID: 7143375
[TBL] [Abstract][Full Text] [Related]
56. Synthesis and preliminary evaluation of a new chelate N2S4 for use in labeling proteins with metallic radionuclides.
Najafi A; Alauddin MM; Siegel ME; Epstein AL
Int J Rad Appl Instrum B; 1991; 18(2):179-85. PubMed ID: 2026493
[TBL] [Abstract][Full Text] [Related]
57. Radiolabeling with technetium-99m to study high-capacity and low-capacity biochemical systems.
Eckelman WC
Eur J Nucl Med; 1995 Mar; 22(3):249-63. PubMed ID: 7789399
[TBL] [Abstract][Full Text] [Related]
58. In the procurement of stable 99mTc labeled protein using bifunctional chelating agent.
Arano Y; Yokoyama A; Magata Y; Horiuchi K; Saji H; Torizuka K
Int J Rad Appl Instrum A; 1986; 37(7):587-92. PubMed ID: 3021660
[TBL] [Abstract][Full Text] [Related]
59. Metallothionein: a bifunctional chelator for the radiolabeling of biologically active molecules.
Morelock MM; Tolman GL
Experientia Suppl; 1987; 52():247-53. PubMed ID: 2959512
[TBL] [Abstract][Full Text] [Related]
60. Serum stability and non-specific binding of technetium-99m labeled diaminodithiol for protein labeling.
Liang FH; Virzi F; Hnatowich DJ
Int J Rad Appl Instrum B; 1987; 14(6):555-61. PubMed ID: 3429236
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
